Thomas P. Howard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thomas P. Howard has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Andrew L. Hong
Department of Pediatrics, Emory University School of Medicine, Atlanta, USA
25 shared publications Xiaofeng Wang
24 shared publications- Andrew O. Giacomelli
Humber Polytechnic, Toronto, Canada
23 shared publications - Elaine M. Oberlick
Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts
22 shared publications - Matthew G. Rees
Broad Institute of MIT and Harvard, Cambridge, USA
22 shared publications Prafulla C. Gokhale
22 shared publications
Latest Publications
- 2 April 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 122 (3) , 752-759
Magnetic Resonance-Guided Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation for Reirradiation in the Abdomen
- 2 April 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 122 (3) , 752-759
Magnetic Resonance-Guided Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation for Reirradiation in the Abdomen
- 1 June 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (6) , 771-777
Evolving Role of Proton Radiation Therapy in Clinical Practice
With the expansion of proton radiation therapy centers across the United States and a gradually expanding body of academic evidence supporting its use, more patients are receiving—and asking about—proton therapy than ever before. Here, we outline, for nonradiation oncologists, the theoretical benefits of proton therapy, the clinical evidence to date, the controversies affecting utilization, and the numerous randomized trials currently in progress. We also discuss the challenges of researching and delivering proton therapy, including the cost of constructing and maintaining centers, barriers with insurance approval, clinical situations in which proton therapy may be approached with caution, and the issue of equitable access for all patients. The purpose of this review is to assist practicing oncologists in understanding the evolving role of proton therapy and to help nonradiation oncologists guide patients regarding this technology.
- 1 June 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (6) , 771-777
Evolving Role of Proton Radiation Therapy in Clinical Practice
With the expansion of proton radiation therapy centers across the United States and a gradually expanding body of academic evidence supporting its use, more patients are receiving—and asking about—proton therapy than ever before. Here, we outline, for nonradiation oncologists, the theoretical benefits of proton therapy, the clinical evidence to date, the controversies affecting utilization, and the numerous randomized trials currently in progress. We also discuss the challenges of researching and delivering proton therapy, including the cost of constructing and maintaining centers, barriers with insurance approval, clinical situations in which proton therapy may be approached with caution, and the issue of equitable access for all patients. The purpose of this review is to assist practicing oncologists in understanding the evolving role of proton therapy and to help nonradiation oncologists guide patients regarding this technology.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Sources and catalog numbers of compounds
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Sources and catalog numbers of compounds
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Purpose:Rhabdoid tumors are devastating pediatric cancers in need of improved therapies. We sought to identify small molecules that exhibit in vitro and in vivo efficacy against preclinical models of rhabdoid tumor.Experimental Design:We screened eight rhabdoid tumor cell lines with 481 small molecules and compared their sensitivity with that of 879 other cancer cell lines. Genome-scale CRISPR–Cas9 inactivation screens in rhabdoid tumors were analyzed to confirm target vulnerabilities. Gene expression and CRISPR–Cas9 data were queried across cell lines and primary rhabdoid tumors to discover biomarkers of small-molecule sensitivity. Molecular correlates were validated by manipulating gene expression. Subcutaneous rhabdoid tumor xenografts were treated with the most effective drug to confirm in vitro results.Results:Small-molecule screening identified the protein-translation inhibitor homoharringtonine (HHT), an FDA-approved treatment for chronic myelogenous leukemia (CML), as the sole drug to which all rhabdoid tumor cell lines were selectively sensitive. Validation studies confirmed the sensitivity of rhabdoid tumor to HHT was comparable with that of CML cell lines. Low expression of the antiapoptotic gene BCL2L1, which encodes Bcl-XL, was the strongest predictor of HHT sensitivity, and HHT treatment consistently depleted Mcl-1, the synthetic-lethal antiapoptotic partner of Bcl-XL. Rhabdoid tumor cell lines and primary-tumor samples expressed low BCL2L1, and overexpression of BCL2L1 induced resistance to HHT in rhabdoid tumor cells. Furthermore, HHT treatment inhibited rhabdoid tumor cell line and patient-derived xenograft growth in vivo.Conclusions:Rhabdoid tumor cell lines and xenografts are highly sensitive to HHT, at least partially due to their low expression of BCL2L1. HHT may have therapeutic potential against rhabdoid tumors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Purpose:Rhabdoid tumors are devastating pediatric cancers in need of improved therapies. We sought to identify small molecules that exhibit in vitro and in vivo efficacy against preclinical models of rhabdoid tumor.Experimental Design:We screened eight rhabdoid tumor cell lines with 481 small molecules and compared their sensitivity with that of 879 other cancer cell lines. Genome-scale CRISPR–Cas9 inactivation screens in rhabdoid tumors were analyzed to confirm target vulnerabilities. Gene expression and CRISPR–Cas9 data were queried across cell lines and primary rhabdoid tumors to discover biomarkers of small-molecule sensitivity. Molecular correlates were validated by manipulating gene expression. Subcutaneous rhabdoid tumor xenografts were treated with the most effective drug to confirm in vitro results.Results:Small-molecule screening identified the protein-translation inhibitor homoharringtonine (HHT), an FDA-approved treatment for chronic myelogenous leukemia (CML), as the sole drug to which all rhabdoid tumor cell lines were selectively sensitive. Validation studies confirmed the sensitivity of rhabdoid tumor to HHT was comparable with that of CML cell lines. Low expression of the antiapoptotic gene BCL2L1, which encodes Bcl-XL, was the strongest predictor of HHT sensitivity, and HHT treatment consistently depleted Mcl-1, the synthetic-lethal antiapoptotic partner of Bcl-XL. Rhabdoid tumor cell lines and primary-tumor samples expressed low BCL2L1, and overexpression of BCL2L1 induced resistance to HHT in rhabdoid tumor cells. Furthermore, HHT treatment inhibited rhabdoid tumor cell line and patient-derived xenograft growth in vivo.Conclusions:Rhabdoid tumor cell lines and xenografts are highly sensitive to HHT, at least partially due to their low expression of BCL2L1. HHT may have therapeutic potential against rhabdoid tumors.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figures S1-S6 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Combined supplementary figures with accompanying legends.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigures S1-S6 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Combined supplementary figures with accompanying legends.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Raw data for follow-up xenograft studies. Note different tabs for each xenograft type.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Raw data for follow-up xenograft studies. Note different tabs for each xenograft type.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Raw data for follow-up xenograft studies. Note different tabs for each xenograft type.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Raw data for follow-up xenograft studies. Note different tabs for each xenograft type.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Purpose:Rhabdoid tumors are devastating pediatric cancers in need of improved therapies. We sought to identify small molecules that exhibit in vitro and in vivo efficacy against preclinical models of rhabdoid tumor.Experimental Design:We screened eight rhabdoid tumor cell lines with 481 small molecules and compared their sensitivity with that of 879 other cancer cell lines. Genome-scale CRISPR–Cas9 inactivation screens in rhabdoid tumors were analyzed to confirm target vulnerabilities. Gene expression and CRISPR–Cas9 data were queried across cell lines and primary rhabdoid tumors to discover biomarkers of small-molecule sensitivity. Molecular correlates were validated by manipulating gene expression. Subcutaneous rhabdoid tumor xenografts were treated with the most effective drug to confirm in vitro results.Results:Small-molecule screening identified the protein-translation inhibitor homoharringtonine (HHT), an FDA-approved treatment for chronic myelogenous leukemia (CML), as the sole drug to which all rhabdoid tumor cell lines were selectively sensitive. Validation studies confirmed the sensitivity of rhabdoid tumor to HHT was comparable with that of CML cell lines. Low expression of the antiapoptotic gene BCL2L1, which encodes Bcl-XL, was the strongest predictor of HHT sensitivity, and HHT treatment consistently depleted Mcl-1, the synthetic-lethal antiapoptotic partner of Bcl-XL. Rhabdoid tumor cell lines and primary-tumor samples expressed low BCL2L1, and overexpression of BCL2L1 induced resistance to HHT in rhabdoid tumor cells. Furthermore, HHT treatment inhibited rhabdoid tumor cell line and patient-derived xenograft growth in vivo.Conclusions:Rhabdoid tumor cell lines and xenografts are highly sensitive to HHT, at least partially due to their low expression of BCL2L1. HHT may have therapeutic potential against rhabdoid tumors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Purpose:Rhabdoid tumors are devastating pediatric cancers in need of improved therapies. We sought to identify small molecules that exhibit in vitro and in vivo efficacy against preclinical models of rhabdoid tumor.Experimental Design:We screened eight rhabdoid tumor cell lines with 481 small molecules and compared their sensitivity with that of 879 other cancer cell lines. Genome-scale CRISPR–Cas9 inactivation screens in rhabdoid tumors were analyzed to confirm target vulnerabilities. Gene expression and CRISPR–Cas9 data were queried across cell lines and primary rhabdoid tumors to discover biomarkers of small-molecule sensitivity. Molecular correlates were validated by manipulating gene expression. Subcutaneous rhabdoid tumor xenografts were treated with the most effective drug to confirm in vitro results.Results:Small-molecule screening identified the protein-translation inhibitor homoharringtonine (HHT), an FDA-approved treatment for chronic myelogenous leukemia (CML), as the sole drug to which all rhabdoid tumor cell lines were selectively sensitive. Validation studies confirmed the sensitivity of rhabdoid tumor to HHT was comparable with that of CML cell lines. Low expression of the antiapoptotic gene BCL2L1, which encodes Bcl-XL, was the strongest predictor of HHT sensitivity, and HHT treatment consistently depleted Mcl-1, the synthetic-lethal antiapoptotic partner of Bcl-XL. Rhabdoid tumor cell lines and primary-tumor samples expressed low BCL2L1, and overexpression of BCL2L1 induced resistance to HHT in rhabdoid tumor cells. Furthermore, HHT treatment inhibited rhabdoid tumor cell line and patient-derived xenograft growth in vivo.Conclusions:Rhabdoid tumor cell lines and xenografts are highly sensitive to HHT, at least partially due to their low expression of BCL2L1. HHT may have therapeutic potential against rhabdoid tumors.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Antibody sources and dilutions
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Antibody sources and dilutions
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figures S1-S6 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Combined supplementary figures with accompanying legends.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigures S1-S6 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Combined supplementary figures with accompanying legends.